SymBiosis logo

SymBiosis

North America, Arkansas, United States, Bentonville

Description

SymBiosis is a venture capital firm.

Investor Profile

SymBiosis has backed more than 12 startups, with 6 new investments in the last 12 months alone. The firm has led 4 rounds, about 33% of its total and boasts 0 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series C, Series B, Series E rounds (top funding stages).
  • Majority of deals are located in United States, Australia, Canada.
  • Strong thematic focus on Biotechnology, Health Care, Life Science.
  • Led 2 rounds in the past year.

Stage Focus

  • Series C (42%)
  • Series B (25%)
  • Series E (17%)
  • Series Unknown (17%)

Country Focus

  • United States (75%)
  • Australia (8%)
  • Canada (8%)
  • France (8%)

Industry Focus

  • Biotechnology
  • Health Care
  • Life Science
  • Pharmaceutical
  • Therapeutics
  • Biopharma
  • Medical
  • Clinical Trials
  • Oncology
  • Precision Medicine
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does SymBiosis frequently co-invest with?

CA
North America, Massachusetts, United States, Boston
Co-Investments: 3
Google Ventures
North America, California, United States, Mountain View
Co-Investments: 2
Seventure Partners
Europe, Ile-de-France, France, Paris
Co-Investments: 2
T. Rowe Price
North America, Maryland, United States, Baltimore
Co-Investments: 2
RA Capital Management
North America, Massachusetts, United States, Boston
Co-Investments: 3
Marshall Wace
Europe, England, United Kingdom, London
Co-Investments: 2
Viking Global Investors
North America, Connecticut, United States, Stamford
Co-Investments: 2
Invus
North America, New York, United States, New York
Co-Investments: 2
ARCH Venture Partners
North America, Illinois, United States, Chicago
Co-Investments: 2
Fidelity
North America, Massachusetts, United States, Boston
Co-Investments: 3

Which angels does SymBiosis often collaborate with?

AG
North America, New Jersey, United States, New Brunswick
Shared Deals: 1

What are some of recent deals done by SymBiosis?

ENTEROME

Paris, Ile-de-France, France

Enterome is a clinical-stage company developing breakthrough immunomodulatory drugs for the treatment of cancer and immune diseases.

BiopharmaBiotechnologyHealth CareLife Science
Series UnknownJun 12, 2025
Amount Raised: $19,000,000
Paradox Immunotherapeutics

Toronto, Ontario, Canada

Paradox Immunotherapeutics is a pharmaceutical company that develops treatments for patients suffering from rare amyloid diseases.

BiotechnologyLife SciencePharmaceutical
Series UnknownFeb 25, 2025
Amount Raised: $10,000,000
AdvanCell

Sydney, New South Wales, Australia

AdvanCell is a clinical-stage radiopharmaceutical company that develops novel cancer therapeutics.

BiotechnologyClinical TrialsOncologyPharmaceutical
Series CFeb 3, 2025
Amount Raised: $112,000,000
Metsera

New York, New York, United States

Metsera is a biopharmaceutical company that develops medicines for obesity and metabolic diseases.

BiopharmaHealth CareMedicalPharmaceutical
Series BNov 13, 2024
Amount Raised: $215,000,000
Evommune

Palo Alto, California, United States

Evommune is a biotechnology company that develops therapeutics that halt progressive disease and address their symptoms.

BiotechnologyHealth CareLife Science
Series COct 31, 2024
Amount Raised: $115,000,000
Seismic Therapeutic

Watertown, Massachusetts, United States

Seismic Therapeutic is a biotechnology company developing machine-learning technology for immunology drug development.

BiotechnologyHealth CareLife ScienceMedical
Series BSep 12, 2024
Amount Raised: $25,000,000
Aardvark Therapeutics

San Diego, California, United States

Aardvark Therapeutics specializes in small molecule therapeutics for obesity and rare genetic metabolic disorders.

BiotechnologyHealth CareTherapeutics
Series CMay 9, 2024
Amount Raised: $85,000,000
Endeavor BioMedicines

Solana Beach, California, United States

Endeavor BioMedicines develops new treatments targeting the underlying causes of pulmonary fibrosis.

BiotechnologyHealth CareMedical
Series CApr 24, 2024
Amount Raised: $132,500,000
Siolta Therapeutics

San Carlos, California, United States

Siolta Therapeutics is a biotech company focused on developing therapeutic microbial consortia to prevent and treat inflammatory diseases.

BiotechnologyTherapeutics
Series CMar 12, 2024
Amount Raised: $12,000,000
FogPharma

Cambridge, Massachusetts, United States

FogPharma is a biopharmaceutical firm that develops precision medicines for the vast majority of therapeutic targets.

BiopharmaBiotechnologyHealth CareLife SciencePharmaceuticalPrecision Medicine
Series EMar 1, 2024
Amount Raised: $145,000,000